Browse treatments

…CC) remains a major cause of cancer-related mortality. Although immunotherapy has demonstrated efficacy in a subset of patients, outcomes var…

…etics in patients with HPV-associated malignancies treated with immunotherapy.3 We evaluated HPV16/18-ctDNA as a predictive biomarker of clin…

…Background PD-1 immunotherapy revolutionized cancer treatment since its approval in 2014 but …

…romising 50% response in the study population who progressed on immunotherapy. Mechanism of the response was investigated through analysis of…

…ody drug conjugates to activate anti-tumor immunity and enhance immunotherapy response.Acknowledgements We gratefully acknowledge Immunomedic…

…es in solid tumors, yet limited data exist in the EMPD context. Adoptive CTL therapy, which involves the ex vivo expansion and activation of autolog…

…y of response and complete tumor regressions when combined with anti-PD-1 immunotherapy.Conclusions Simultaneously inducing cancer cell death and activ…

…th PEG-ADA enhances anti-tumor immunity and sensitizes NSCLC to immunotherapy.Conclusions Our study uncovers a previously unrecognized immuno…

…s effective in improving practical K/C regarding integration of neoadjuvant IO into practice. The data also support the importance of reinforc…

…r increased presence has been associated with poor responses to immunotherapy in solid tumors. While much of current research focuses on thei…

…Background Immunotherapy has limited efficacy in treating solid tumor. The main hurdles …

…Background Immunotherapy has transformed treatment paradigms in many malignancies but re…